NCT01072331View on ClinicalTrials.gov

Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MP-513

MP-513 10 mg, once a day, for 4 weeks

DRUG

MP-513

MP-513 20 mg, once a day, for 4 weeks

DRUG

Placebo of MP-513

MP-513 placebo, once a day, for 4 weeks

Trial Locations (1)

Unknown

Suita

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY